CLINICAL TRIALS PROFILE FOR GABLOFEN
✉ Email this page to a colleague
All Clinical Trials for GABLOFEN
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT01520545 ↗ | Safety Study of 3 mg/mL Baclofen Injection (Intrathecal) Using A Programmable Pump | Completed | Mallinckrodt | Phase 3 | 2012-12-01 | Safety study to assess the 3 mg/mL baclofen injection (intrathecal) using a programmable pump |
| NCT01520545 ↗ | Safety Study of 3 mg/mL Baclofen Injection (Intrathecal) Using A Programmable Pump | Completed | Piramal Critical Care, Ltd. | Phase 3 | 2012-12-01 | Safety study to assess the 3 mg/mL baclofen injection (intrathecal) using a programmable pump |
| NCT01821560 ↗ | Baclofen Effects in Cigarette Smokers | Completed | National Institute on Drug Abuse (NIDA) | Phase 2 | 2013-03-01 | The proposed project will utilize perfusion functional magnetic resonance imaging (fMRI), a functional candidate gene association approach (of dopaminergic addictions-targeted polymorphisms), and the dopamine-modulating and gamma-aminobutyric acid (GABA) B receptor agonist, baclofen, to examine the brain and behavioral responses in smokers to appetitive smoking reminders (cues that motivate continued smoking and relapse). These studies will provide a means to identify an appetitive cue-sensitive pharmacologic-responsive endophenotype. Once brain/behavioral/genetic endophenotypes can be determined prior to treatment, smoking cessation treatments can be structured to meet individual needs, which will significantly improve treatment outcome. |
| NCT01821560 ↗ | Baclofen Effects in Cigarette Smokers | Completed | National Institutes of Health (NIH) | Phase 2 | 2013-03-01 | The proposed project will utilize perfusion functional magnetic resonance imaging (fMRI), a functional candidate gene association approach (of dopaminergic addictions-targeted polymorphisms), and the dopamine-modulating and gamma-aminobutyric acid (GABA) B receptor agonist, baclofen, to examine the brain and behavioral responses in smokers to appetitive smoking reminders (cues that motivate continued smoking and relapse). These studies will provide a means to identify an appetitive cue-sensitive pharmacologic-responsive endophenotype. Once brain/behavioral/genetic endophenotypes can be determined prior to treatment, smoking cessation treatments can be structured to meet individual needs, which will significantly improve treatment outcome. |
| NCT01821560 ↗ | Baclofen Effects in Cigarette Smokers | Completed | University of Pennsylvania | Phase 2 | 2013-03-01 | The proposed project will utilize perfusion functional magnetic resonance imaging (fMRI), a functional candidate gene association approach (of dopaminergic addictions-targeted polymorphisms), and the dopamine-modulating and gamma-aminobutyric acid (GABA) B receptor agonist, baclofen, to examine the brain and behavioral responses in smokers to appetitive smoking reminders (cues that motivate continued smoking and relapse). These studies will provide a means to identify an appetitive cue-sensitive pharmacologic-responsive endophenotype. Once brain/behavioral/genetic endophenotypes can be determined prior to treatment, smoking cessation treatments can be structured to meet individual needs, which will significantly improve treatment outcome. |
| NCT02011516 ↗ | Baclofen Effects on Marijuana Dependence | Completed | Pennsylvania Department of Health | Phase 2 | 2013-12-01 | Studies show that certain reminders of drug use such as the sight of someone using marijuana, pictures of blunts, particular moments throughout the day, prompt marijuana users to smoke marijuana. We are measuring the brain and behavioral responses of marijuana dependent individuals to these reminders (cues) We will examine brain responses during cue exposure and determine whether these responses are associated with treatment outcome. We are testing the hypothesis that the medication baclofen reduces brain responses during marijuana cue exposure and/or craving in marijuana dependent individuals. Baclofen is FDA-approved for other uses, but not for the treatment of marijuana dependence. Functional magnetic resonance imaging (fMRI) will be used to measure the brain's response to marijuana cues. fMRI is a painless technique that takes special pictures of the brain (or other parts of your body). It does not involve radiation or injections. Eligible participants will have a 50% chance of receiving placebo (sugar pill) and a 50% chance of receiving baclofen. Neither the participant nor study personnel will know whether participants are receiving baclofen or placebo. Participants will also receive twice weekly psychosocial treatment with a certified clinician. Twelve weeks of treatment will be followed by a 12 week follow up. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for GABLOFEN
Condition Name
Clinical Trial Locations for GABLOFEN
Trials by Country
Clinical Trial Progress for GABLOFEN
Clinical Trial Phase
Clinical Trial Sponsors for GABLOFEN
Sponsor Name
